Key facts
- AgomAb’s last known valuation is $415.6M.
- It has raised $334.0M across 1 recorded rounds; the latest was Later Stage VC (Series C) ($100.7M) in Oct 2023.
- Notable investors include Fidelity Management & Research Company, Canaan Partners, The Invus Group, Cormorant Asset Management, EQT Life Sciences — 17 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for AgomAb
Funding rounds
1 roundsAbout AgomAb
Developer of fibrotic disease treatments intended to preserve and restore organ function in fibrotic. The company specializes in growth factor biology and offers treatment that simulates molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune, and degenerative diseases, enabling healthcare professionals to treat the patients more efficiently.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Antwerp, Belgium
- Founded
- 2017
- Employees
- 65
- Website
- agomab.com/
- Ownership
- Privately Held (backing)
AgomAb doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AgomAb shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AgomAb in its N-PORT filings yet. We sweep new filings monthly.